Original title: 17 AstraZeneca employees were arrested on suspicion of fraudulent insurance, the pharmaceutical giant stood at a crossroads
Our reporter Zhang Min
AstraZeneca employees are suspected of fraudulent insurance, there is a new development.
On the evening of February 10, the official WeChat account of Shenzhen Medical Insurance Bureau “Shenzhen Medical Insurance” released the “Abbreviated case report on the case of AstraZeneca Pharmaceutical Co., Ltd. staff suspected of defrauding medical insurance funds”, stating that in July 2021, Shenzhen Medical Insurance Bureau According to After reporting the clues, the verification found that the staff of AstraZeneca Pharmaceutical Co., Ltd. were suspected of fraud and insurance fraud, and then under the guidance of the National Medical Insurance Bureau, the Shenzhen Municipal Public Security Bureau and other relevant units carried out a special investigation and handling. After meticulous work, the case was successfully cracked, a fraud gang suspected of tampering with the genetic test results of tumor patients to defraud medical insurance funds, 17 persons involved in the case were arrested, and criminal compulsory measures were taken in accordance with the law.
In response to this matter, a reporter from “Securities Daily” contacted AstraZeneca for an interview. A relevant person from the company told reporters that the company has no further information to respond.
In this regard, lawyer Yang Zhaoquan, director of Beijing Weinuo Law Firm, said in a reply to the reporter’s interview that if it is not an employee in an important position, the impact on the company should not be large.
The National Medical Insurance Bureau has stepped up efforts to rectify fraudulent insurance
On the eve of the Spring Festival of the Year of the Tiger, the National Medical Insurance Administration released the article “Response to the AstraZeneca Pharmaceutical Co., Ltd. Staff Suspected of Defrauding Medical Insurance Funds”, which caused a sensation in the industry.
According to the above-mentioned documents, in response to the suspected tampering of the genetic test results of tumor patients by the staff of AstraZeneca Pharmaceuticals Co., Ltd. to defraud the medical insurance fund, the person in charge of the Fund Supervision Department of the National Medical Insurance Bureau stated that in the early stage, based on the clues reported by the masses, the National Medical Insurance Bureau urged Shenzhen to establish a A joint task force composed of medical insurance, public security, health, market supervision and other departments conducted an in-depth investigation of the case, and all the suspects have been arrested.
Recently, the National Medical Insurance Administration and the Ministry of Public Security conducted an interview with the relevant person in charge of AstraZeneca China, informed the progress of the phased investigation of the case, and asked AstraZeneca China to strictly abide by laws and regulations, fully cooperate with relevant departments in the follow-up investigation, and immediately Carry out internal investigation and rectification, plug loopholes in marketing supervision, strengthen law-abiding education for employees, effectively enhance the awareness of integrity, and timely expose the situation of interviews and rectification. AstraZeneca China, in accordance with the interview requirements, promptly communicated with the Shenzhen Municipal Medical Insurance Bureau and the Public Security Bureau to do a good job in the follow-up investigation of the case, urged employees who have similar behaviors to voluntarily surrender, and announced the case and self-inspection and rectification on the company’s official website.
In the next step, the National Medical Insurance Bureau will cooperate with the Ministry of Public Security and the National Health and Health Commission to carry out special rectification nationwide to tamper with the results of genetic testing to defraud medical insurance funds.
Regarding the above-mentioned suspected fraudulent insurance, AstraZeneca’s official website introduced that in August 2021, AstraZeneca found in its internal compliance inspection that a small number of employees in Shenzhen had tampered with or participated in tampering with patient test reports, suspected of defrauding medical insurance funds. . The company attaches great importance to this, sincerely accepts the guidance and suggestions of the National Medical Insurance Bureau and the public security department, and will fully implement relevant requirements, further strengthen management and supervision, and continuously improve employees’ awareness of laws and regulations to ensure that legal compliance is implemented to each employee. in daily work.
China’s performance is expected to decline this year
China is one of AstraZeneca’s most important markets and a growth engine for the company. The company’s key therapeutic areas include respiratory, cardiovascular, metabolic, oncology, digestive, renal and rare diseases, among which the oncology area includes osimertinib mesylate tablets, gefitinib tablets, and durvalumab injection and other products. Currently, AstraZeneca has a total market value of about $181.6 billion.
On February 10, AstraZeneca announced its 2021 results. For the whole year, the company achieved revenue of US$37.417 billion, a year-on-year increase of 41%, and net profit attributable to common shareholders of the parent company was US$112 million, down 96.5% year-on-year; in the fourth quarter, it increased by 62% to US$12.011 billion, the fourth quarter. The net profit attributable to ordinary shareholders of the parent company in the fiscal quarter was -347 million US dollars, a year-on-year decrease of 134.29%.
China is one of the important sources of AstraZeneca’s revenue, with revenue of US$6.011 billion in 2021, a year-on-year increase of 12%. However, the China business fell 4% year-on-year for the first time in the fourth quarter, and revenue fell to $1.312 billion from $1.362 billion in the same period in fiscal 2020. AstraZeneca expects a mid-single-digit decline in performance in China in 2022, mainly due to the continued impact of centralized procurement and medical insurance.
It is worth mentioning that since last year, the AstraZeneca business team has continued to adjust. Among them, on December 9, 2021, AstraZeneca announced that Yin Min, general manager of its China Oncology Division, will resign, and the last working day is December 31. On February 10, He Shu, the head of AstraZeneca and the county team, really resigned, becoming one of the many executives who left AstraZeneca.
In addition, on the evening of January 4, 2022, the listed companyJunshi BiologyThe announcement stated that on December 31, 2021, the company and AstraZeneca signed the “Termination Agreement of the Exclusive Promotion Agreement”, and the company took back the promotion rights of toripalimab injection agreed in the original agreement. It is understood that the cooperation between Junshi Bio and AstraZeneca was reached on February 28, 2021. The cooperation between the two parties has only been 10 months. The end of the cooperation in such a short time has attracted market attention.
Massive information, accurate interpretation, all in Sina Finance APP
Responsible editor: Deng Jian